Jeff Fairman

This profile gathers the share dealings of Jeff Fairman in Vaxcyte, Inc., where the filings describe the role as senior executive. Between 7 June 2021 and 26 October 2022, the trades on record add up to 19 filings.

Every open-market trade on record is a sale: 7 sales worth €1.2M. The rest of the record consists of 2 share grants and 10 option exercises. Since January 2022: no purchases and 7 sales on the market.

The record was last updated on 28 October 2022 with an open-market sale (€396k) in Vaxcyte, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.